Efficacy of Galectin-3C in Mouse Model of Metastatic Breast Cancer
Annual rept. 1 Jul 1998-30 Jun 1999
NORTHERN CALIFORNIA INST FOR RESEARCH AND EDUCATION SAN FRANCISCO
Pagination or Media Count:
The goal of this research is to evaluate a potential therapeutic agent for breast cancer based on the lectin galectin-3. The hypothesis to be tested is that therapy with an N-terminally truncated form of galectin-3 galectin-3C will be efficacious for inhibition of metastases. The overall purpose of the research is to determine the efficacy, safety and mechanism of action of galectin-3C in treatment of metastatic breast cancer. To this end, recombinant galectin-3 was produced from which galectin-3C was derived by collagenase enzyme digestion and affinity chromatography. For ELISA detection of injected galectin-3C in nude mice, chickens were immunized with galectin-3C but the response yielded only low affinity antibody. An alternative detection strategy was developed by metabolically labeling galectin-3 with 35 methionine prior to collagenase cleavage. The maximum tolerated dose of galectin-3C in nude mice at 5 days was determined to be a minimum of 125 mgkg without adverse effects.
- Medicine and Medical Research